Portland patients are advised to maintain consistent hydration, eat small frequent meals to prevent nausea, and report any severe abdominal pain or persistent vomiting to their healthcare provider immediately
doi: 10.1016/j.biopha.2023.114590 508 LewinskaAAdamczykJPajakJStoklosaSKubisBPastuszekPet al
Her family history of type 2 diabetes, which is closely associated with obesity, is big part of why she wants to lose weight and keep it off
Ozempic is the brand name of semaglutide, a once-weekly injectable drug developed by Danish pharmaceutical company Novo Nordisk and approved by the FDA for the treatment of Type 2 diabetes in 2017
Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network (2022) Changes in glucose metabolism and glycemic status with once-weekly subcutaneous semaglutide 2.4 mg among participants with prediabetes in the STEP program, Diabetes Care (2022) What causes obesity & overweight?, Eunice Kennedy Shriver National Institute of Child Health and Human Development (2021) Compounding and the FDA: Questions and Answers, Food and Drug Administration (2024) Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes, Reviews in Endocrine and Metabolic Disorders (2022) FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products, Food and Drug Administration (2024) Thinking of using a compounding pharmacy
& Bean, B
